Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(OTCBB:RGBP) Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell For Solid Tumors

|Includes: Regen Biopharma, Inc. (RGBP)

www.smallcapsolutions.com

www.regenbiopharmainc.com (OTCQB:RGBP)

Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors

Company Augments Potency of its Existing NR2F6 Silenced CAR-T Approach By Leveraging Innate Immune Activation Molecules

The filing of an application for a United States patent covering synergies between NR2F6 gene-silenced CAR T cells combined with proprietary activators of the innate immune system. While previous work demonstrated that methodologies developed by Regen (protected under Regen's issued US patent #9,091,696) are useful in stimulation of T cell activity, the current application further modifies T cells to express molecules that act as a localized "danger signal" to the immune system.

Remarkable clinical results have been obtained by numerous investigators utilizing CAR T cells in the treatment of leukemia and lymphomas

http://finance.yahoo.com/news/regen-biopharma-inc-files-patent-133000462.html

Recent News Items of Interest:

Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

http://finance.yahoo.com/news/regen-biopharma-submits-application-fda-133000880.html

Regen BioPharma, Inc. and the National Institutes of Health to Collaborate

http://finance.yahoo.com/news/regen-biopharma-inc-national-institutes-133000075.html

Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXelleratehttp://finance.yahoo.com/news/regen-biopharma-inc-receives-fda-133000659.html

We believe Regen is a Long Play with imminent Short Term Gain potential.

They are a "Cutting Edge" Bio Tech - Stem Cell R&D Company that offers exponential growth.

Regen in our opinion will one day be either the Leader in many areas of Stem Cell treatment and/or could be a very attractive Candidate for a Buy Out or Merger.

Areas of Focus are:

Various Cancers and the treatment of - Breast, Liver, Kidney, Prostate

(dCellVax is on the verge of & awaits FDA clearance for Phase I Human/Patient clinical trials for Breast Cancer)

Treatment of Rare Blood Disorders & Diseases (HemaXellerate FDA "Cleared/Approved " for Human/Patient clinical trials (aPlastic Anemia) Phase I to commence soon.

Treatment of Leukemia

We can Assist any Publicly Traded Company Gain Greater Exposure Creating Increased Awareness and Liquidity in the Market Place (Retail or Private)

** Contact us for Custom Tailored Plans for Your situation

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.